Premium
PRELIMINARY SAFETY DATA FROM PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) B‐CELL MALIGNANCIES TREATED WITH THE NOVEL B‐CELL LYMPHOMA 2 (BCL2) INHIBITOR BGB‐11417
Author(s) -
Cheah C. Y.,
Verner E.,
Tam C. S.,
Hilger J.,
Gao Y.,
Huang J.,
Simpson D.,
Opat S.
Publication year - 2021
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.85_2881
Subject(s) - medicine , follicular lymphoma , mantle cell lymphoma , venetoclax , neutropenia , tolerability , lymphoma , adverse effect , pharmacokinetics , refractory (planetary science) , oncology , febrile neutropenia , pharmacology , gastroenterology , leukemia , toxicity , chronic lymphocytic leukemia , biology , astrobiology
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom